For thrombocytopenia, hemolytic anemia, or other aPL-mediated hematological and microthrombotic manifestations or noncriteria manifestations; an alternative option for CAPS which is refractory to standard treatment, refractory obstetric APS, and pediatric CAPS (2, 33, 35). This evidence concerns the gene FASLG and Thrombocytopenia.